Bourse CDTRP KFOC Research Innovation – Dre Sunita Singh

Grâce à sa collaboration avec des organisations partenaires, le PRDTC est heureux d’annoncer les résultats de son Concours annuel de subventions à la recherche et à l’innovation visant à financer de nouveaux projets passionnants. Au cours des prochaines semaines, nous présenterons tous les projets financés dans le cadre du concours 2022.

Bourse CDTRP KFOC Research Innovation 

Dre Sunita Singh

  • Affiliation principale : University Health Network
  • Thème 5 – Rétablir la santé à long terme
  • Titre : The efficacy, mechanisms and safety of SGLT2i and GLP1RA combination therapy in kidney transplant recipients: The HALLMARK study

Résumé (en anglais) 

Kidney transplant recipients (KTR) are at high risk of death from heart disease after transplantation, as well as graft failure, where the kidney transplant no longer works and dialysis or another kidney transplant is required. New types of drugs called sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP1RA) have been developed as treatments for diabetes. These drugs have since been shown to lower blood pressure, weight and protein in the urine, and when used in combination, the beneficial effects are enhanced. These drugs also decrease the risk of heart attack, kidney failure or dying from heart or kidney disease. It is not known if these drugs have the same beneficial effects in KTR.  The objective of this study is to determine if using combination therapy with SGLT2i and GLP1RA is better than either drug alone. We are conducting a trial with 20 KTR where participants will be treated with GLP1RA or SGLT2i alone, followed by the combination of SGLT2i and GLP1RA. Participants will be treated for a total of 12 weeks. People with and without diabetes will be included. We will compare differences on kidney function, heart function as well as metabolic risk factors (i.e., blood sugar, cholesterol and weight) with combination therapy versus SGLT2i or GLP1RA alone. We will closely monitor side effects during the trial. This study will allow us to understand if combination therapy is safe and effective in protecting KTR from heart and kidney disease in the future.